Brent Stewart
Pain Medicine · Newberry, FLNPI 1548374085
Payments from drug & device makers
Across 556 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$3K
- Boston Scientific$2K
- Pfizer$787
- Amgen$643
- Foundation Fusion Solutions, LLC$640
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$530
- plus $3K from 27 others
What the payments were for
- Food & beverage$9,907100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166 | $2,541 |
| Boston Scientific | 91 | $2,113 |
| Pfizer | 47 | $787 |
| Amgen(2 entities) | 48 | $643 |
| Foundation Fusion Solutions, LLC | 26 | $640 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 30 | $530 |
| Scilex Pharmaceuticals Inc. | 21 | $325 |
| Biodelivery Sciences International, Inc. | 24 | $291 |
| AbbVie | 14 | $226 |
| Vertos Medical, Inc. | 5 | $213 |
| SPR Therapeutics, Inc | 8 | $209 |
| Teva Pharmaceuticals USA, Inc. | 10 | $158 |
| Lilly USA, LLC | 6 | $123 |
| Virtus Pharmaceuticals LLC | 7 | $122 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $117 |
| Almatica Pharma LLC | 7 | $113 |
| Biohaven Pharmaceuticals, Inc. | 5 | $109 |
| Supernus Pharmaceuticals, Inc. | 4 | $103 |
| Redhill Biopharma Inc. | 5 | $87 |
| Medtronic | 1 | $73 |
| MDD US Operations, LLC | 4 | $64 |
| Arbor Pharmaceuticals, Inc. | 3 | $49 |
| Daiichi Sankyo Inc. | 3 | $49 |
| Bioventus LLC | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Inari Medical, Inc. | 1 | $30 |
| Valinor Pharma, LLC | 1 | $22 |
| Zyla Life Sciences, Inc. | 1 | $18 |
| Relievant Medsystems, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Biogen | 1 | $12 |
| Assertio Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,907 in reported general payments places this provider in the 75th percentile of 596 pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 351 | $173,710 |
| BelbucaBuprenorphine Hcl | 179 | $125,032 |
| Buprenorphine | 219 | $42,548 |
| Nucynta ErTapentadol Hcl | 49 | $33,712 |
| OxycontinOxycodone Hcl | 58 | $26,850 |
| MovantikNaloxegol Oxalate | 66 | $26,398 |
| ZtlidoLidocaine | 38 | $24,299 |
| Nurtec OdtRimegepant Sulfate | 19 | $22,309 |
| Fentanyl | 202 | $20,937 |
| LyricaPregabalin | 17 | $20,332 |
| Morphine Sulfate ErMorphine Sulfate | 802 | $19,219 |
| UbrelvyUbrogepant | 19 | $18,465 |
| Tramadol Hcl ErTramadol Hcl | 275 | $17,486 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 787 | $17,172 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $16,267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er, Nucynta | $2,541 | $336,121591 claims |
| PfizerNurtec Odt, Lyrica | $787 | $42,64136 claims |
| Redhill Biopharma Inc.Movantik | $87 | $26,39866 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $325 | $24,29938 claims |
| AbbVieUbrelvy | $226 | $18,46519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 596 pain medicine providers in Florida.
Other pain medicine in Newberry
- Anand PatelOrmond Beach$20.4M
- Julio PaezClermont$2.3M
- Joseph PergolizziNaples$2.1M
- Abel MurilloMiami$1.6M
- George MonluxPalm Coast$1.3M
- Ferdinand FormosoJacksonville$1M
- Cesar LassalleOrlando$1M
- Robert GuirguisTampa$895K
- Ashraf HannaClearwater$608K
- Peter MichaelCoral Gables$496K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.